Hikma cuts generics guidance for third time this year
Drugs developer Hikma Pharmaceuticals (HIK) continues to struggle with its generics business. The £2.35bn FTSE 250 company has cut its sales guidance for the third time this year sparking a major sell-off in its shares. The stock...
09 November 2017
